Priming of mesenchymal stem cells with a hydrosoluble form of curcumin allows keeping their mesenchymal properties for cell-based therapy development.
NDS27
curcumin
cyclodextrin
equine MSCs
mdMSC
mesenchymal stem cells
mitochondria
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
27
01
2021
received:
11
12
2020
accepted:
08
02
2021
pubmed:
27
3
2021
medline:
5
10
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Mesenchymal stem cells are increasingly studied for their use as drug-carrier in addition to their intrinsic potential for regenerative medicine. They could be used to transport molecules with a poor bioavailability such as curcumin in order to improve their clinical usage. This natural polyphenol, well-known for its antioxidant and anti-inflammatory properties, has a poor solubility that limits its clinical potential. For this purpose, the use of NDS27, a curcumin salt complexed with hydroxypropyl-beta-cyclodextrin (HPβCD), displaying an increased solubility in aqueous solution, is preferred. This study aims to evaluate the uptake of NDS27 into skeletal muscle-derived mesenchymal stem cells (mdMSCs) and the effects of such uptake onto their mesenchymal properties. It appeared that the uptake of NDS27 into mdMSCs is concentration-dependent and not time-dependent. The use of a concentration of 7 µmol/L which does not affect the viability and proliferation also allows preservation of their adhesion, invasion and T cell immunomodulatory abilities.
Identifiants
pubmed: 33769687
doi: 10.1111/jcmm.16403
pmc: PMC8107093
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Drug Carriers
0
2-Hydroxypropyl-beta-cyclodextrin
1I96OHX6EK
Curcumin
IT942ZTH98
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4877-4881Subventions
Organisme : Service Public de Wallonie
ID : WALInnov program
Organisme : Service Public de Wallonie
ID : convention number 1610151
Organisme : Fondation Universitaire de Belgique
Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Int J Nanomedicine. 2016 Dec 22;12:167-178
pubmed: 28053531
J Biomed Mater Res A. 2013 Dec;101(12):3592-8
pubmed: 23744789
Int J Mol Sci. 2017 Oct 07;18(10):
pubmed: 28991167
J Cell Mol Med. 2021 May;25(10):4877-4881
pubmed: 33769687
Cell Death Discov. 2015 Oct 26;1:15017
pubmed: 27551451
J Cell Physiol. 2018 Feb;233(2):830-848
pubmed: 28059453
J Pharmacol Sci. 2016 Nov;132(3):192-200
pubmed: 27840063
Biomed Pharmacother. 2019 Jan;109:1268-1275
pubmed: 30551377
Protein Cell. 2017 Jun;8(6):439-445
pubmed: 28271444
J Transl Med. 2020 Jan 30;18(1):42
pubmed: 32000804
Stem Cells Int. 2015;2015:638153
pubmed: 26074974
Int J Mol Sci. 2017 Aug 25;18(9):
pubmed: 28841158